Methods of treating psoriasis with secukinumab
AssigneeNovartis AG
InventorsAchim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
Life of this patent
Estimating the term…
Abstract
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
Claims11
A method of treating psoriasis, comprising administering to a patient in need thereof about 150 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter.
A method of treating psoriasis, comprising administering to a patient in need thereof about 150 mg secukinumab by subcutaneous injection 4 or 5 times in a month and every 4 weeks thereafter, wherein the secukinumab administrations in the month are separated by about one week.
A method of treating moderate to severe plaque psoriasis, comprising administering to a patient in need thereof about 150 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until the patient achieves a Psoriasis Area and Severity Index (PASI) 90 response.
Dependencies are inferred from the claim text.